Thymidine kinase (tk-1) in prognostic indices for dlbcl
AssigneeRoche Diagnostics Operations, Inc.
InventorsVinzent Rolny, Sandra Rutz, David Morgenstern, Boris Pinchuk, Christina Zimmermann, Martin Klammer, Franziska Sonner
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.
Claims15
A method of determining a prognostic index (PI) (also called risk score or PI-score) for a diffuse large B-cell lymphoma (DLBCL) patient the method comprising
- a) determining at least the following parameters:
- i) extranodal disease status;
- ii) Ann Arbor stage;
- and iii) the level of thymidine kinase 1,
- wherein absence of extranodal disease values 0 points and presence of extranodal disease values 1 point,
- wherein an Ann Arbor stage of I or II values 0 points and an Ann Arbor stage of III or IV values 1 point, and
- wherein a level of the thymidine kinase up to and including the cut-off values 0 points and wherein a level of the thymidine kinase above cut-off values at least 1 point, and
- b) summing up the values for i), ii) and iii) in the determination of the PI.
Use of a value for the level of TK-1 in the determination of a prognostic index for patients with DLBCL.
A prognostic index (PI) for DLBCL comprising a value for the level of thymidine kinase 1.
Dependencies are inferred from the claim text.